Skip to main content
. 2022 Jan 17;12:793107. doi: 10.3389/fphar.2021.793107

FIGURE 6.

FIGURE 6

Therapeutic efficacy of aspirin in altering levels of the CXCL4 protein induced by hyperoxia in NF-κB-luciferase+/+ transgenic mice, as detected using immunohistochemical (IHC) staining (A) Images of alveoli; scale bars for the upper panel represent 200 µm and middle panel represent 50 µm (B) Images of bronchi; scale bars for the upper panel represent 200 µm and middle panel represent 50 µm (C) Images of blood vessels. Scale bars for the upper panel represent 200 µm and middle panel represent 50 µm. DAB-specific threshold selection (red selection) was performed using ImageJ software. NF-κB-luciferase+/+ transgenic mice were assigned to four groups (n = 6 mice per group): Mock group, treatment with PBS at 0, 24 and 48 h, and exposure to hyperoxia for 72 h. A25 group, treatment with 25 μg/g aspirin at 0, 24 and 48 h, and exposure to hyperoxia for 72 h. A50 group: treatment with 50 μg/g aspirin at 0, 24 and 48 h, and exposure to hyperoxia for 72 h.